Drug Combination Therapy of Glioblastoma

Dear Colleagues,

Glioblastoma is still the most devastating cancer of the central nervous system, and standard treatment options are mostly palliative. In the last decade, despite the discovery of novel therapeutic targets, many monotherapeutic strategies have failed in clinical trials; therefore, there is an urgent need to develop novel treatment schemes. Combined therapy in glioma seems to be a promising solution, but for now, it remains a challenging endeavor rather than a real clinical treatment option. Glioblastoma is a complex disease presenting features such as inter-/intratumor heterogeneity, altered metabolism, high proliferation rate, hypoxic niches, drug resistance, immunosuppression, infiltrative nature, necrosis, neoangiogenesis, and self-renewal. The design of efficient polypharmacotherapy requires, on one hand, ensuring synergistic drug action on strategic targets in tumors, and on the other, facilitating drug transport across the blood–brain barrier, delivery to glioma cells, internalization and controlled release, and maintenance of a stable and controlled blood drug level.

This Special Issue will highlight the role of combination therapy of glioblastoma, its preclinical aspects, limitations, potential advantages/disadvantages, and current status.

Prof. Dr. Ewa Obuchowicz
Dr. Anna Bielecka-Wajdman
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.